| Description | Epimedokoreanin B (EKB), an isoprenylated flavonoid isolated from Korean Epimedium, exhibited anticancer activity in human non-small cell lung cancer (NSCLC) A549 and NCI-H292 cells.Epimedokoreanin B also possesses anti-inflammatory and antibacterial activities, and may have scavenging activity against DPPH radicals, inhibiting the proliferation of MCF-7 and HepG2 in a dose-dependent manner. Epimedokoreanin B also exhibits anti-inflammatory and antibacterial activity, with DPPH radical scavenging activity, and inhibits the proliferation of MCF-7 and HepG2 in a dose-dependent manner.Epimedokoreanin B significantly inhibits the formation of N (α)-(carboxymethyl)lysine (CML) and N (Ï)-(carboxymethyl)arginine (CMA), and prevents clinical complications of diabetes mellitus through the inhibition of advanced glycation end-products (AGEs). |
| In vitro | Epimedokoreanin B（化合物6）在3.13-25 μM浓度、作用48小时条件下，对肺癌细胞A549、Calu1、H1299的增殖显示了显著的抑制作用，并且对人支气管上皮细胞BEAS-2B无毒性。[1] 在5 μM浓度、24小时的条件下，Epimedokoreanin B抑制了CD163表达和IL-10产生，这是M2型标志物的已知表现，表明Epimedokoreanin B抑制了人单核细胞衍生的巨噬细胞（HMDM）中M2型极化，并且抑制了HMDM中STAT3的激活。[4] Epimedokoreanin B的处理不仅抑制了A549和NCI-H292细胞的增殖和迁移，并伴随着细胞质内的空泡化现象，还观察到Epimedokoreanin B处理的细胞中出现了自噬体积累和自噬流的阻断，这与内质网应激的发生一致。[2] |
| molecular weight | 422.47 |
| Molecular formula | C25H26O6 |
| CAS | 161068-53-7 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Zhang H, et al. Flavonoids from the leaves of Epimedium Koreanum Nakai and their potential cytotoxic activities. Nat Prod Res. 2020;34(9):1256-1263. 2. Zheng H, et al. Epimedokoreanin B inhibits the growth of lung cancer cells through endoplasmic reticulum stress-mediated paraptosis accompanied by autophagosome accumulation. Chem Biol Interact. 2022;366:110125. 3. Kariu T, et al. Inhibition of gingipains and Porphyromonas gingivalis growth and biofilm formation by prenyl flavonoids. J Periodontal Res. 2017;52(1):89-96. 4. Pan C, et al. Flavonoid Compounds Contained in Epimedii Herba Inhibit Tumor Progression by Suppressing STAT3 Activation in the Tumor Microenvironment. Front Pharmacol. 2020;11:262. |